The treatment of bladder cancer has evolved over time to encompass not only the traditional
modalities of chemotherapy and surgery, but has been particularly impacted by the use of …

Cytotoxic chemotherapy has been the only systemic treatment of locally advanced and
metastatic urothelial carcinoma for decades. Long-term survival remains stagnant around 12 …

Purpose Recent observations have focused attention on the means that human tumors
employ to evade host defense systems critical to immune surveillance. The concepts of …

Introduction Until recently, systemic chemotherapy was the only option for treating bladder
cancer and outcomes remained dismal. After a long gap of no progress for 40 years …

Purpose Over the past 3 decades, no major treatment breakthrough has been reported for
advanced bladder cancer. Recent Food and Drug Administration (FDA) approval of five …

Bladder cancer is one of the most significant genitourinary cancer, causing high morbidity
and mortality in a great number of patients. Over the years, various treatment methods for …

Abstract Treatment options for metastatic urothelial carcinoma (mUC) remained relative
unchanged over the last 30 years with combination chemotherapy as the mainstay of …

Bladder cancer is the sixth most common cancer in the US and most tumors have urothelial
(transitional cell) histology. Platinum-based chemotherapy has long been the standard of …

Purpose: We review the biological mechanisms of action, clinical safety and efficacy of
immunotherapies for urothelial carcinoma. We also describe current areas of research in …

Simple Summary In this review, we examined relevant clinical trial results with immune
checkpoint inhibitors in patients with metastatic urothelial cancer. We also focused on the …